Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Uliledlimab |
| Trade Name | |
| Synonyms | TJD5|TJ-4309|TJ00-4309|TJ4309|TJ004309 |
| Drug Descriptions |
Uliledlimab (TJ004309) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 31461341). |
| DrugClasses | Adenosine Targeting 24 CD73 Antibody 14 |
| CAS Registry Number | NA |
| NCIT ID | C159168 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Uliledlimab | Atezolizumab Uliledlimab | 0 | 1 |
| Toripalimab-tpzi + Uliledlimab | Toripalimab-tpzi Uliledlimab | 0 | 0 |
| Uliledlimab | Uliledlimab | 0 | 1 |